Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech for less than cash value -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (13)	4/7/2002 12:08:25 PM
From: benchpress550	Read Replies (1) \| Respond to of 684

If I read RZYM web site right, HCV phase 2 should be done at the end of 2002. The study is to suppose to use 72 people for 12 weeks of trials(should this be finish faster than the end of the year?) Good question about HCV not being positive will the company still be around. They have two other drugs in the pipeline and are coming up with another one. My best guess this could be another GLIA clone stock if they dont have good results. The reason why I like CALP is they are making a profit and are increasing sales. Plus insitutionals own 63% of the float. I do not know anything about AGNT and I do not own or never have own any their stock. The reason is I do not know how to value the quality of their chemistry and their losses rose 98 percent.